199 related articles for article (PubMed ID: 33646314)
1. Association of Anti-Tumor Necrosis Factor Therapy With Mortality Among Veterans With Inflammatory Bowel Disease.
Cohen-Mekelburg S; Wallace BI; Van T; Wiitala WL; Govani SM; Burns J; Lipson R; Yun H; Hou J; Lewis JD; Dominitz JA; Waljee AK
JAMA Netw Open; 2021 Mar; 4(3):e210313. PubMed ID: 33646314
[TBL] [Abstract][Full Text] [Related]
2. Increased Mortality Rates With Prolonged Corticosteroid Therapy When Compared With Antitumor Necrosis Factor-α-Directed Therapy for Inflammatory Bowel Disease.
Lewis JD; Scott FI; Brensinger CM; Roy JA; Osterman MT; Mamtani R; Bewtra M; Chen L; Yun H; Xie F; Curtis JR
Am J Gastroenterol; 2018 Mar; 113(3):405-417. PubMed ID: 29336432
[TBL] [Abstract][Full Text] [Related]
3. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppressant medications and mortality in inflammatory bowel disease.
Lewis JD; Gelfand JM; Troxel AB; Forde KA; Newcomb C; Kim H; Margolis DJ; Strom BL
Am J Gastroenterol; 2008 Jun; 103(6):1428-35; quiz 1436. PubMed ID: 18494836
[TBL] [Abstract][Full Text] [Related]
5. Trends of Utilization of Tumor Necrosis Factor Antagonists in Children With Inflammatory Bowel Disease: A Canadian Population-Based Study.
El-Matary W; Leung S; Tennakoon A; Benchimol EI; Bernstein CN; Targownik LE
Inflamm Bowel Dis; 2020 Jan; 26(1):134-138. PubMed ID: 31323083
[TBL] [Abstract][Full Text] [Related]
6. Mortality Risk of Inflammatory Bowel Disease: A Case-Control Study of New York State Death Records.
Nocerino A; Feathers A; Ivanina E; Durbin L; Swaminath A
Dig Dis Sci; 2019 Jun; 64(6):1604-1611. PubMed ID: 30604370
[TBL] [Abstract][Full Text] [Related]
7. The Impact of Intestinal Complications on Health Care Costs Among Patients With Inflammatory Bowel Disease Treated With Anti-Tumor Necrosis Factor Therapies.
Rubin DT; Griffith J; Zhang Q; Hepp Z; Keshishian A
Inflamm Bowel Dis; 2021 Jul; 27(8):1201-1209. PubMed ID: 33107564
[TBL] [Abstract][Full Text] [Related]
8. Anti-Tumor Necrosis Factor Therapy and Risk of Kidney Function Decline and Mortality in Inflammatory Bowel Disease.
Sumida K; Shrestha P; Mallisetty Y; Thomas F; Gyamlani G; Streja E; Kalantar-Zadeh K; Kovesdy CP
JAMA Netw Open; 2024 Apr; 7(4):e246822. PubMed ID: 38625700
[TBL] [Abstract][Full Text] [Related]
9. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A
Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916
[TBL] [Abstract][Full Text] [Related]
10. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
Thomsen SB; Ungaro RC; Allin KH; Elmahdi R; Poulsen G; Andersson M; Colombel JF; Jess T
Aliment Pharmacol Ther; 2022 May; 55(9):1128-1138. PubMed ID: 35080036
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing the outcome of vedolizumab treatment: Real-life data with objective outcome measurements.
Mader O; Juillerat P; Biedermann L; Michetti P; Hruz P; Pittet V; Rogler G; Zahnd-Straumann N; Seibold F
United European Gastroenterol J; 2021 Apr; 9(3):398-406. PubMed ID: 33203339
[TBL] [Abstract][Full Text] [Related]
12. Impact of antitumour necrosis factor therapy on surgery in inflammatory bowel disease: a population-based study.
Hawthorne AB; Arms-Williams B; Cannings-John R; Pollok RCG; Berry A; Harborne P; Trivedi A
BMJ Open Gastroenterol; 2024 May; 11(1):. PubMed ID: 38777566
[TBL] [Abstract][Full Text] [Related]
13. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
[TBL] [Abstract][Full Text] [Related]
14. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
[TBL] [Abstract][Full Text] [Related]
15. Temporal Trends in Initiation of Therapy With Tumor Necrosis Factor Antagonists for Patients With Inflammatory Bowel Disease: A Population-based Analysis.
Targownik LE; Tennakoon A; Leung S; Lix LM; Singh H; Bernstein CN
Clin Gastroenterol Hepatol; 2017 Jul; 15(7):1061-1070.e1. PubMed ID: 28238957
[TBL] [Abstract][Full Text] [Related]
16. No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Québec Provincial Database From 1996 to 2015.
Verdon C; Reinglas J; Coulombe J; Gonczi L; Bessissow T; Afif W; Vutcovici M; Wild G; Seidman EG; Bitton A; Brassard P; Lakatos PL
Inflamm Bowel Dis; 2021 Apr; 27(5):655-661. PubMed ID: 32676662
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroid Sparing in Inflammatory Bowel Disease is More Often Achieved in the Immunomodulator and Biological Era-Results from the Dutch Population-Based IBDSL Cohort.
Jeuring SFG; Biemans VBC; van den Heuvel TRA; Zeegers MP; Hameeteman WH; Romberg-Camps MJL; Oostenbrug LE; Masclee AAM; Jonkers DMAE; Pierik MJ
Am J Gastroenterol; 2018 Mar; 113(3):384-395. PubMed ID: 29317770
[TBL] [Abstract][Full Text] [Related]
18. Conventional therapy for moderate to severe inflammatory bowel disease: A systematic literature review.
Damião AOMC; de Azevedo MFC; Carlos AS; Wada MY; Silva TVM; Feitosa FC
World J Gastroenterol; 2019 Mar; 25(9):1142-1157. PubMed ID: 30863001
[TBL] [Abstract][Full Text] [Related]
19. A Population-Based Study of Combination vs Monotherapy of Anti-TNF in Persons With IBD.
Elias ED; Targownik LE; Singh H; Bernstein CN
Inflamm Bowel Dis; 2020 Jan; 26(1):150-157. PubMed ID: 31340002
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
